

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/815,330	03/23/2001	John A. Zaia	1954-333	4689
6449	7590 05/30/2003			
ROTHWELL, FIGG, ERNST & MANBECK, P.C. 1425 K STREET, N.W. SUITE 800 WASHINGTON, DC 20005			EXAMINER	
			SCHEINER, LAURIE A	
			ART UNIT	PAPER NUMBER
			1648	17
•			DATE MAILED: 05/30/2003	•

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 09/815,330

Applicant(s)

Zaia et al.

Examiner

Laurie Scheiner

Art Unit 1648



The MAILING DATE of this communication appears on the cover sheet with the correspondence address					
Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.					
 If the period for reply specified above is less than thirty (30) days, a reply within t If NO period for reply is specified above, the maximum statutory period will apply Failure to reply within the set or extended period for reply will, by statute, cause t Any reply received by the Office later than three months after the mailing date of earned patent term adjustment. See 37 CFR 1.704(b). 	and will expire SIX (6) MONTHS from the mailing date of this communication. the application to become ABANDONED (35 U.S.C. § 133).				
Status					
1) 🛛 Responsive to communication(s) filed on <i>May 15,</i>	2003				
2a) This action is FINAL . 2b) This act	tion is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.					
Disposition of Claims					
4) 💢 Claim(s) <u>2 and 23</u>	is/are pending in the application.				
4a) Of the above, claim(s)	is/are withdrawn from consideration.				
5) 💢 Claim(s) 2	is/are allowed.				
6) 💢 Claim(s) 23	is/are rejected.				
7)					
	are subject to restriction and/or election requirement.				
Application Papers					
9) The specification is objected to by the Examiner.					
10) ☐ The drawing(s) filed on is/are a) ☐ accepted or b) ☐ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
11) The proposed drawing correction filed on	is: a) \square approved b) \square disapproved by the Examiner.				
If approved, corrected drawings are required in reply to this Office action.					
12) The oath or declaration is objected to by the Examiner.					
Priority under 35 U.S.C. §§ 119 and 120					
13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a) □ All b) □ Some * c) □ None of:					
1. Certified copies of the priority documents have been received.					
2. U Certified copies of the priority documents have been received in Application No					
application from the International Bure					
*See the attached detailed Office action for a list of the certified copies not received.					
 14) ☑ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e). a) ☐ The translation of the foreign language provisional application has been received. 					
15) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.					
Attachment(s)					
1) X Notice of References Cited (PTO-892)	4) Interview Summary (PTO-413) Paper No(s).				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal Patent Application (PTO-152)				
3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)					

Application/Control Number: 09/815,330 Page 2

Art Unit: 1648

Claims 2 and 23 are pending.

Claim 2 is allowable.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claim 23 is rejected under 35 U.S.C. 103(a) as being unpatentable over Diamond et al. (US Patent No. 6,156,317) in view of Gallina et al. (JOURNAL OF VIROLOGY, 1999 February, 73 (2) 1468-78).

Diamond et al. clearly teach a mutant cytomegalovirus protein (pp65) which elicits a CTL response against cells infected with cytomegalovirus. Please see throughout for peptides and immunologically functional variants that can activate CTLs without active viral replication, which may be used for eliciting a cellular immune response against HCMV.

Diamond et al. are essentially silent with respect to pp65 having a protein kinase activity, or lack of it with respect to the variant peptides.

Gallina et al. teach that wild-type pp65 may not in fact be responsible for the protein kinase activity since a recognizable kinase consensus is lacking. Gallina et al. conclude that Plk1, or the pp65-Plk1 association may be responsible for the kinase activity. Thus, experiments are inconclusive with respect to pp65 possessing protein kinase activity. That is, whether or not all isolated pp65 is inherently lacking in protein kinase function is unclear.

Application/Control Number: 09/815,330 Page 3

Art Unit: 1648

Taken with the teachings of Gallina et al., Diamond et al. teach that which is broadly claimed since both wild-type, and mutant pp65 would inherently lack kinase activity due to absence of a required structure/function consensus.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Laurie Scheiner, whose telephone number is (703) 308-1122. Due to a flexible work schedule, the examiner's hours typically vary each day. However, the examiner can normally be reached Monday thru Friday. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel, can be reached on (703) 308-4027.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group 1600 receptionist whose telephone number is (703) 308-0196.

Correspondence related to this application may be submitted to Group 1600 by facsimile transmission. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). Official communications should be directed toward one of the following Group 1600 fax numbers: (703) 308-4242, (703) 305-3014, (703) 872-9306 or (703) 872-9307. Informal communications may be submitted directly to the Examiner through the following fax number: (703) 746-5226.

 (\bigcirc)

Laurie Scheiner/LAS May 26, 2003

> LAURIE SCHEINER PRIMARY EXAMINER